AlphAIAlphAI — Financial news for AI agents
investing.comOCT 232 min read$RDY

Dr. Reddy’s Q2FY27 slides: base growth masks lenalidomide drag

Dr. Reddy’s Laboratories reported fiscal Q2 2027 revenues of ₹8,671 crores, down 1.5% YoY but up 7% sequentially. EBITDA margin was 20.6%, with profit after tax at ₹925 crores. North America sales declined 23% YoY due to lenalidomide, but other regions showed growth. The company announced strategic partnerships and product developments, including a dengue vaccine and biosimilars. Shares rose 0.45% to $13.29 post-results.

Original reporting
investing.com
Published Oct 23, 2026, 3:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 23, 2026, 3:28 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$RDY
Neutral
high confidence
Mentioned
$RDY
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$RDYNeutralMed
01

Why it matters

Earnings provide fresh data on revenue, margins, and guidance, influencing short-term price action.

02

Market read

Earnings release offers modest trading opportunity; base growth may support price, but lenalidomide drag poses risk.

03

What to watch

Potential upside from upcoming biosimilar approvals and CDMO revenue growth.

Relevance 7/10Novelty 8/10Timing: post-market today

Background

Dr. Reddy's reported Q2FY27 results, highlighting base business growth and lenalidomide sales decline.

Company-level read

Ticker impact

$RDYNeutralHigh confidence
Context

Q2FY27 earnings released with revenue decline and lenalidomide sales drop, new guidance and margins disclosed.

Expected impact

likely slight upward pressure as investors view base growth positively, though lenalidomide drag could cap gains

Evidence & confidence

First report of quarterly results with fresh numbers; market reaction was a 0.45% rise, indicating limited but positive bias.

Market effects

Sector

Pharma sector may see mixed sentiment as generic growth offsets loss of lenalidomide exclusivity.

Regional

Indian market outlook improves with domestic revenue growth.

Global

Limited, primarily affects RDY and peers in generics.

Counterpoint

What could challenge this read

Lenalidomide decline could signal broader margin pressure if other exclusivity losses follow.

Key entities

  • Company
    Dr. Reddy's Laboratories

    Indian pharmaceutical company reporting Q2FY27 results.

Read at source← All news

StoryDr. Reddy's Laboratories reports Q2 FY27 profit decline amid lenalidomide sales drop

Also covered by

1 outlet

Related articles

OCT 23
$RDYMed

Dr. Reddy's Laboratories Profit Drops In Q2

Dr. Reddy's Laboratories reported a 36% drop in Q2 profit to INR 9,134 million, or INR 11.10 per share, from the prior year. Revenue declined to INR 86,708 million, driven by lower lenalidomide sales in North America. Pre-market trading showed a 0.76% increase to $13.32 on the NYSE.

rttnews.com1 min
AUG 14
$RDYMed

Dr. Reddy's Hyderabad Facility Receives Four Observations from USFDA

Dr. Reddy’s Laboratories said the US FDA inspected its Hyderabad formulations facility FTO-3 (Bachupally) from Aug 6-14, 2026 and issued a Form 483 listing four observations. The company must prepare and implement a remediation plan within the US FDA’s timeline. Investors may watch for updates on corrective actions and closure.

whalesbook.com2 min
AUG 1
$RDYMedAI 9/10

Dr. Reddy's Laboratories wins US FDA approval for rituximab biosimilar

Dr. Reddy’s Laboratories said the US FDA approved its rituximab biosimilar, a version of Rituxan, produced at its Hyderabad facility. The company said Fresenius Kabi will manage US marketing. Dr. Reddy’s said the product is already available in India, Europe, and more than 25 emerging markets, where rituximab treats non-Hodgkin lymphoma and some autoimmune diseases.

newsbytesapp.com2 min
AUG 1
$RDYMedAI 8/10

Dr. Reddy's Laboratories: Receives U.S. FDA Approval for Rituximab Biosimilar

Dr. Reddy’s Laboratories said the U.S. FDA approved its rituximab biosimilar on Aug. 1, 2026 for certain B-cell malignancies and autoimmune conditions. Under a strategic deal, Fresenius Kabi will have exclusive rights to market and distribute the product in the U.S. The company cited a successful FDA pre-license inspection at its Bachupally, Hyderabad facility.

investywise.com3 min